VU0453379
CAS No. : 1638646-27-1
| Size | Price | Stock |
|---|---|---|
| 5mg | $250 | In-stock |
| 10mg | $390 | In-stock |
| 25mg | $720 | In-stock |
| 50mg | $1100 | In-stock |
| 100mg | $1650 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-116819 |
| M.Wt: | 434.57 |
| Formula: | C26H34N4O2 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
VU0453379 is a blood-brain barrier permeable GLP-1R positive allosteric modulator (PAM) with an EC50 value of 1.3 μM. VU0453379 potentiates the actions of endogenous GLP-1 and synthetic peptide agonists, and promotes GLP-1 receptor internalization. VU0453379 stimulates insulin secretion from primary mouse islets. VU0453379 enhances the function of endogenous GLP-1R and reverses catalepsy in animal models. VU0453379 is useful for research on Parkinson's disease and type 2 diabetes[1]. IC50 & Target:EC50: 1.3 μM (GLP-1R)[1] In Vitro:VU0453379 (1.3-30 μM) potentiates native GLP-1, exenatide, and liraglutide in human GLP-1R 9-3-H cells with EC50 values ranging from 1.8 μM to 30 μM, acts as an ago-PAM alone, and enhances GLP-1 receptor internalization without significant β-arrestin recruitment effects[1]. In Vivo:VU0453379 (10-30 mg/kg; i.p.; single administration) dose-dependently reverses haloperidol (HY-14538)-induced catalepsy in rats[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- VU0453379
- Cat. No.:
- HY-116819
- Quantity:
Your information is safe with us.